| November 10th, 2023 |
Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders |
| October 09th, 2023 |
Sirius Therapeutics Raised Nearly US$100 Million to Accelerate Clinical Development of siRNA Therapeutics |
| August 07th, 2022 |
Sirius Therapeutics appoints Dr. Qunsheng Ji CEO and to the Board of Directors |
